iodoazomycin arabinoside profile

iodoazomycin arabinoside: marker of tissue hypoxia; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5241817
SCHEMBL ID	12071282
MeSH ID	M0192133

Synonym
iodoazomycin arabinoside
SCHEMBL12071282

Excerpt	Reference	Relevance
" Pharmacokinetic characterization of radiopharmaceuticals, specifically radiopharmaceuticals for imaging tissue hypoxia, has not been a central theme in their development."	( Pharmacokinetics of SPECT radiopharmaceuticals for imaging hypoxic tissues. Stypinski, D; Wiebe, LI, 1996)	0.29
" Our results confirm that 123I-IAZA has appropriate pharmacokinetic and radiopharmacokinetic properties to support clinical hypoxia imaging."	( Clinical pharmacokinetics of 123I-IAZA in healthy volunteers. McEwan, AJ; Mercer, JR; Schmidt, RP; Stypinski, D; Tam, YK; Wiebe, LI, 1999)	0.3
" Radiation dose estimates obtained from the tissue activity levels for this period were calculated from pharmacokinetic (WinNonlin) and dosimetry (MIRD and RAdiation Dose Assessment Resource) parameters."	( [131I]Iodoazomycin arabinoside for low-dose-rate isotope radiotherapy: radiolabeling, stability, long-term whole-body clearance and radiation dosimetry estimates in mice. Kumar, P; McEwan, AJ; McQuarrie, SA; Wiebe, LI; Zhou, A, 2005)	0.33

Excerpt	Relevance	Reference
" However, radioactivity in the blood of patients and healthy volunteers dosed with [123I]IAZA has a protracted terminal elimination phase in which clearance is influenced by free [123I]IAZA and possibly by unidentified metabolites."	( [131I]IAZA as a molecular radiotherapeutic (MRT) drug: wash-out with cold IAZA accelerates clearance in a murine tumor model. McEwan, AJ; Mercer, JR; Wiebe, LI, 2013)	0.39

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	16 (59.26)	18.2507
2000's	5 (18.52)	29.6817
2010's	4 (14.81)	24.3611
2020's	2 (7.41)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (3.70%)	5.53%
Reviews	2 (7.41%)	6.00%
Case Studies	1 (3.70%)	4.05%
Observational	0 (0.00%)	0.25%
Other	23 (85.19%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
methoxyflurane Methoxyflurane: An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with NITROUS OXIDE to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180). methoxyflurane : An ether in which the two groups attached to the central oxygen atom are methyl and 2,2-dichloro-1,1-difluoroethyl.	2	1	0	ether; organochlorine compound; organofluorine compound	hepatotoxic agent; inhalation anaesthetic; nephrotoxic agent; non-narcotic analgesic
galactose galactopyranose : The pyranose form of galactose.	2.61	2	0	D-galactose; galactopyranose	Escherichia coli metabolite; mouse metabolite
thiazoles [no description available]	2.02	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
azomycin azomycin: RN given refers to parent cpd with specified locant; structure	7.56	25	1	C-nitro compound; imidazoles	antitubercular agent
technetium Technetium: The first artificially produced element and a radioactive fission product of URANIUM. Technetium has the atomic symbol Tc, and atomic number 43. All technetium isotopes are radioactive. Technetium 99m (m=metastable) which is the decay product of Molybdenum 99, has a half-life of about 6 hours and is used diagnostically as a radioactive imaging agent. Technetium 99 which is a decay product of technetium 99m, has a half-life of 210,000 years.	3.09	1	0	manganese group element atom
misonidazole Misonidazole: A nitroimidazole that sensitizes normally radio-resistant hypoxic cells to radiation. It may also be directly cytotoxic to hypoxic cells and has been proposed as an antineoplastic.	3.79	3	0
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	2.07	1	0	D-glucopyranose	epitope; mouse metabolite
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.02	1	0	organic bromide salt	colorimetric reagent; dye
fluoromisonidazole [no description available]	2.07	1	0
glycosides [no description available]	2.07	1	0
18f-faza fluoroazomycin arabinoside: used for hypoxia-specific imaging; structure in first source	2.07	1	0
technetium tc 99m exametazime Technetium Tc 99m Exametazime: A gamma-emitting RADIONUCLIDE IMAGING agent used in the evaluation of regional cerebral blood flow and in non-invasive dynamic biodistribution studies and MYOCARDIAL PERFUSION IMAGING. It has also been used to label leukocytes in the investigation of INFLAMMATORY BOWEL DISEASES.	2.68	3	0

Condition	Relationship Strength	Studies
Amyloid Deposits [description not available]	2.6	1
Acute Confusional Senile Dementia [description not available]	2.6	1
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.6	1
Anoxemia [description not available]	2.93	4
Cancer of Prostate [description not available]	2.71	3
Hypoxia Sub-optimal OXYGEN levels in the ambient air of living organisms.	7.93	4
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.71	3
Experimental Neoplasms [description not available]	2.92	4
Hepatocellular Carcinoma [description not available]	2.11	1
Cancer of Liver [description not available]	2.11	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.11	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.11	1
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	3.04	1
Carcinoma, Anaplastic [description not available]	3.04	1
Cancer of Nasopharynx [description not available]	3.04	1
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	3.04	1
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	3.04	1
Benign Neoplasms [description not available]	2.92	4
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.92	4
Experimental Mammary Neoplasms [description not available]	2.02	1
Diabetic Feet [description not available]	1.98	1
Autoimmune Diabetes [description not available]	1.98	1
Diabetes Mellitus, Adult-Onset [description not available]	1.98	1
Diabetic Angiopathies VASCULAR DISEASES that are associated with DIABETES MELLITUS.	1.98	1
Diseases, Peripheral Vascular [description not available]	1.98	1
Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.	1.98	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	1.98	1
Peripheral Vascular Diseases Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.	1.98	1
Diabetic Foot Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION.	1.98	1
Carcinoma, Oat Cell [description not available]	2.38	2
Benign Neoplasms, Brain [description not available]	1.98	1
Carcinoma, Epidermoid [description not available]	1.98	1
Astrocytoma, Grade IV [description not available]	1.98	1
Cancer of Head [description not available]	1.98	1
Cancer of Lung [description not available]	2.38	2
Sarcoma, Epithelioid [description not available]	1.98	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	1.98	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	1.98	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	1.98	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	1.98	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.38	2
Sarcoma A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.	1.98	1
Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.	1.98	1
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	2.38	2
Cerebral Ischemia [description not available]	1.99	1
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	1.99	1
Brain Vascular Disorders [description not available]	2	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2	1
Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.	2	1
Acute Brain Injuries [description not available]	2	1
Anoxia, Brain [description not available]	2	1
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	2	1

iodoazomycin arabinoside

Description

Cross-References

Synonyms (2)

Research Excerpts

Pharmacokinetics

Dosage Studied

Research

Studies (27)

Study Types

iodoazomycin arabinoside

Description

Cross-References

Synonyms (2)

Research Excerpts

Pharmacokinetics

Dosage Studied

Research

Studies (27)

Study Types

Related Drugs (12)

Related Conditions (52)